Searchable abstracts of presentations at key conferences in endocrinology

ea0087p15 | Poster Presentations | UKINETS2022

Management and outcome of pituitary metastasis from a bronchial carcinoid tumour presenting with ocular symptoms

Shah Husnain , Ayuk John

Metastasis to the pituitary gland is a rare occurrence. Here we discuss our experience managing a patient with pituitary neuroendocrine metastasis who first presented with ocular symptoms. A 65-year-old lady presented in July 2015 with progressive diplopia. An MRI scan revealed a pituitary mass lesion with aggressive features and two abnormal enhancing nodules within the brain white matter, raising suspicion of metastatic disease. Radiotherapy was commenced on the basis that t...

ea0068p15 | Abstracts | UKINETS2019

Surgical correction of carcinoid heart disease improves liver function, 5HIAA levels and subjective assessment of carcinoid symptoms

Shah Husnain , Sagar Vandana , Venkataraman Hema , Steeds Rick , Rooney Stephen , Shah Tahir

Introduction: Neuroendocrine tumours of the gastrointestinal tract often cause carcinoid syndrome and in advance cases carcinoid heart disease. These tumours secrete serotonin, which can bind to heart valves and cause fibrosis and eventually valve incompetence. Most cases involve the tricuspid valve +/− pulmonary valve. Medical management comprises diuretics for fluid overload and somatostatin analogues to reduce circulating serotonin. Definitive treatment is heart-valve...

ea0076p5 | Abstracts | CHD2021

Nutritional recovery is essential for successful management of patients with advanced carcinoid heart disease

Shah Husnain , Mair Reena , Arif Sayqa , Smith Stacey , Vickrage Suzanne , Kemp-Blake Joanne , Denham Samuel , Oelofse Tessa , Singh Harjot , Singh Stephen , Steeds Richard , Shah Tahir

Introduction Chronic heart failure is a catabolic state leading to cachexia in 5-15% of patients, predicting poor survival outcomes. Malnutrition affects 40% of patients with NETs and 58% with carcinoid syndrome (CS). Case 45M with severe carcinoid heart disease, on referral and admission was cachectic with BMI of 16, having lost 32 kg or 30% of body weight, meeting 50% of dietary requirements and at risk of refeeding syndrome. Nasogastric feeding (NG) w...

ea0087p9 | Poster Presentations | UKINETS2022

Ocular neuroendocrine tumour metastases – presentation & outcome

Shah Husnain , Roji Mohamad , Ekmekcioglu Ozgul , Ayuk John , Smith Stacey , Khan Zaira , Vickrage Suzanne , Kemp-Blake Joanne , Humphries Sian , Hughes Simon , Diaz-Cano Salvador , Elshafie Mona , Karkhanis Salil , Shetty Shishir , Geh Ian , Shah Tahir

Introduction: Here we present our experience of managing patients with orbital well-differentiated neuroendocrine tumour (NET) metastases.Methods: Six patients were identified from the hospital NET database: four male; two female.Results: Median age at diagnosis of primary NET: 69.5 years (range: 40-74 years). Three patients were alive at time of data capture. Of those who passed away: mean survival from diagnosis of primary NET = ...

ea0072p4 | (1) | UKINETS2020

Telotristat in the management of Carcinoid diarrhoea – real world experience of patients from an ENETs centre of excellence in Neuroendocrine tumours.

Khanna Amardeep , Cianci Nicole , Abbas Shah Husnain , Goel Ashish , Jebril Asma , Chauhan Jessica , Pipe Michelle , Shetty Shishir , Weston Christopher , Venkataraman Hema , Smith Stacey , Vickrage Suzanne , Kemp-Blake Joanne , Shah Tahir

Carcinoid syndrome occurs in 20% patients, presenting with flushing, abdominal pain, diarrhoea, and wheeze and can be challenging to manage. The standard of care for carcinoid syndrome is somatostatin analogues (SSAs) with add-on Creon, codeine and loperamide therapy. Nonetheless, half of patients experience debilitating diarrhoea. Telotristat-ethyl is a peripheral tryptophan-hydroxylase inhibitor approved for treatment of diarrhoea, supported by Phase 3 clinical trials but la...

ea0072p13 | (1) | UKINETS2020

Well-differentiated Gastroenteropancreatic G3 NET: Findings from a large single centre cohort

Lithgow Kirstie , Venkataraman Hema , Hughes Simon , Shah Husnain , Kemp-Blake Joanne , Vickrage Suzanne , Smith Stacey , Humphries Sian , Elshafie Mona , Taniere Philipe , Diaz-Cano Salvador , Dasari Bobby , Almond Max , Ford Sam , Ayuk John , Shetty Shishir , Shah Tahir , Geh Ian

Purpose: Neuroendocrine neoplasms are known to have heterogeneous biological behavior. G3 neuroendocrine tumours (NET G3) are characterized by well-differentiated morphology and Ki67>20%. The prognosis of this disease is understood to be intermediate between NET G2 and neuroendocrine carcinoma (NEC). Clinical management of NET G3 is challenging due to limited data to inform treatment strategies.Methods: We describe clinical characteristics, treatment, an...